CD5-positive follicular lymphoma: a case report and literature review

Intern Med. 2011;50(8):899-904. doi: 10.2169/internalmedicine.50.4339. Epub 2011 Apr 15.

Abstract

A 59-year-old man exhibited an enlarged right inguinal lymph node in February 2009. A pathological diagnosis of follicular lymphoma (FL), grade 3A, was made based on a biopsy specimen from the right inguinal lymph node. The immunophenotypes of the lymphoma cells were CD3-, CD5+, CD7-, CD10+, CD19+, CD20+, CD23+, IgM+, Igκ-, and Igλ+. Fluorescence-activated cell sorting (FACS) dual staining indicated that the cells were double-positive for both CD5 and CD20. Mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL) and CD5-positive diffuse large B-cell lymphoma (DLBCL) were ruled out by the presence of cyclin D1-, CD10+, and the pathological findings. Based on these findings, the patient was diagnosed as having CD5-positive FL. Eight cycles of rituximab plus six cycles of CHOP were performed, and complete remission was achieved. To our knowledge, this is a rare case of CD5-positive FL. A literature review suggested a relatively higher incidence in younger and male patients. Remarkably, patients with grade 3 tend to undergo a transformation from CD5-positive FL to DLBCL.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CD5 Antigens / metabolism*
  • Cyclophosphamide / therapeutic use
  • Diagnosis, Differential
  • Disease Progression
  • Doxorubicin / therapeutic use
  • Humans
  • Immunophenotyping
  • Lymphoma, Follicular / immunology*
  • Lymphoma, Follicular / pathology*
  • Lymphoma, Follicular / therapy
  • Lymphoma, Large B-Cell, Diffuse / immunology
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • Middle Aged
  • Prednisone / therapeutic use
  • Prognosis
  • Rituximab
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • CD5 Antigens
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol